Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131

Inclusion criteria

• Patients with a confirmed diagnosis of multiple myeloma (> 10% plasma cells on a previous myelogram)
• Secretion of a monoclonal immunoglobulin
• No myelodysplasia evaluated by myelogram
• Disease refractory or relapsed after at least 3 lines of therapy
• Patients with a dated and signed the consent form
• Collection of autologous peripheral blood stem cells containing at least 2. 106 CD 34 + cells / kg
• Age> 18 years
• Performance status <2 (see Annex I), life expectancy of more than 3 months
• No chemotherapy or radiotherapy within 4 weeks before inclusion
• No major surgery within 4 weeks preceding the assessment of inclusion
• No bisphosphonates within 2 weeks prior radioimmunotherapy, except for treatment started more than three months ago.
• Normality of the biological assessment:
• Creatinine less than or equal to 1.5 times the normal laboratory
• Liver: less than or equal to 1.5 times the normal laboratory (free and conjugated bilirubin, SGOT, SGPT, gamma GT PAL)
• Hemoglobin ≥ 8 g/mm3
• ≥ 3 WBC 000/mm3
• Neutrophils ≥ 1 500/mm3
• Platelets ≥ 100 000/mm3

Exclusion criteria

Patients with other cancers except uterine carcinoma in situ or basal cell skin carcinoma

• Patients with other (s) condition (s) Severe (s) to prevent tolerance to study and conduct the study to completion
• Patient is pregnant or unwilling to take a contraceptive treatment for three months after treatment
• Collection of peripheral blood stem cells containing less than 2106 CD 34 + cells / kg
• Patients enrolled in another experimental treatment protocol
• Patients who already received treatment with radioimmunotherapy
• Myelodysplasia assessed by myelogram
• Patient with thyroid
• Patient unable to sign informed consent ÉcouterLire phonétiquement